Business Description
Equillium Inc
NAICS : 325412
SIC : 2834
ISIN : US29446K1060
Total Employee Number:
14Description
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 88.62 | |||||
Equity-to-Asset | 0.94 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 39.1 | |||||
3-Year EPS without NRI Growth Rate | 30.6 | |||||
3-Year FCF Growth Rate | -14.2 | |||||
3-Year Book Growth Rate | -20.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 72.87 | |||||
9-Day RSI | 64.72 | |||||
14-Day RSI | 61.91 | |||||
3-1 Month Momentum % | 53.72 | |||||
6-1 Month Momentum % | 96.6 | |||||
12-1 Month Momentum % | 832.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 18.62 | |||||
Quick Ratio | 18.62 | |||||
Cash Ratio | 18.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.3 | |||||
Shareholder Yield % | -18.62 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -70.75 | |||||
ROA % | -60.07 | |||||
ROIC % | -2072.31 | |||||
3-Year ROIIC % | -72.28 | |||||
ROC (Joel Greenblatt) % | -2919.05 | |||||
ROCE % | -74.91 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 5.6 | |||||
PB Ratio | 3.28 | |||||
Price-to-Tangible-Book | 3.29 | |||||
EV-to-EBIT | -6.58 | |||||
EV-to-EBITDA | -6.62 | |||||
EV-to-Forward-Revenue | 0.08 | |||||
EV-to-FCF | -7.1 | |||||
Price-to-GF-Value | 30.95 | |||||
| Price-to-Net-Current-Asset-Value | 3.33 | |||||
| Price-to-Net-Cash | 3.4 | |||||
Earnings Yield (Greenblatt) % | -15.2 | |||||
FCF Yield % | -9.7 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EQ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Equillium Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.32 | ||
| Beta | 2.676 | ||
| 3-Year Sharpe Ratio | 0.75 | ||
| 3-Year Sortino Ratio | 3.09 | ||
| Volatility % | 351.62 | ||
| 14-Day RSI | 61.91 | ||
| 14-Day ATR ($) | 0.266166 | ||
| 20-Day SMA ($) | 2.90425 | ||
| 12-1 Month Momentum % | 832.26 | ||
| 52-Week Range ($) | 0.2924 - 3.45 | ||
| Shares Outstanding (Mil) | 63.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Equillium Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Equillium Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 136 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 45 days | ||
| Guidance call for 2026 | 2026-06-03 16:55 | 2.79 (+5.48%) | ||
| General meeting for 2026 | 2026-05-28 13:00 | 2.63 (+13.36%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 2.27 (+1.79%) | ||
| Annual report for 2025 | 2026-03-25 | 1.95 (-2.99%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-25 | 1.95 (-2.99%) | ||
| 38th Annual Roth Conference | 2026-03-23 08:30 | 2.13 (-1.39%) | ||
| Guidance call for 2026 | 2026-03-11 10:40 | 1.97 (-1.99%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 0.92 (-5.71%) |
Show
Entries
Equillium Inc Frequently Asked Questions
What is Equillium Inc(EQ)'s stock price today?
The current price of EQ is $3.10. The 52 week high of EQ is $3.45 and 52 week low is $0.29.
When is next earnings date of Equillium Inc(EQ)?
The next earnings date of Equillium Inc(EQ) is 2026-08-14 Est..
Does Equillium Inc(EQ) pay dividends? If so, how much?
Equillium Inc(EQ) does not pay dividend.
Guru Commentaries on NAS:EQ
No articles.
Press Release
Articles on Equillium Inc
No articles.
Headlines
See More- 1
Jun 09, 2026
Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK
Seeking Alpha • 4:18am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers